Table 4.

Univariate and multivariate analysis of overall survival

Covariables	Hazard ratio	95% CI	p value
Univariate analysis
PLR ≥ 150	1.151	0.772–1.715	0.494
NLR ≥ 2.5	1.175	0.806–1.714	0.401
LMR ≥ 2.5	0.488	0.317–0.751	0.001
Age	1.037	1.013–1.060	0.002
Sex (female)	0.831	0.481–1.436	0.507
Pathological stage			0.026*
Stage I	1.000
Stage II	1.718	1.148–2.571	0.009
Stage III	1.980	0.975–4.017	0.059
Stage IV	2.296	0.317–16.631	0.411
Histological type			0.999*
Adenocarcinoma	1.000
Squamous cell carcinoma	0.991	0.651–1.509	0.967
Large cell carcinoma	1.041	0.518–2.091	0.909
Other	0.986	0.135–7.190	0.989
Multivariate analysis
LMR ≥ 2.5	0.546	0.352–0.846	0.007
Age	1.041	1.017–1.066	0.001
Sex
Male	1.000		0.966
Female	1.013	0.564–1.819
Pathological stage			0.013*
I	1.000
II	1.783	1.179–2.697	0.006
III	2.144	1.047–4.389	0.037
IV	4.083	0.521–31.995	0.180
Histological type			0.830*
Adenocarcinoma	1.000
Squamous cell carcinoma	0.812	0.525–1.255	0.348
Large cell carcinoma	0.923	0.457–1.864	0.824
Other	0.929	0.122–7.056	0.943

LMR lymphocyte-to-monocyte ratio, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio

^*Linear trend p value